Storia in 2 fonti

Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic

A series of label expansions for Sanofi and Regeneron’s Dupixent, including its key 2024 FDA

Raccontata da

fiercepharma.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 g fa

Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic

A series of label expansions for Sanofi and Regeneron’s Dupixent, including its key 2024 FDA

originale

endpoints.news1 g fa

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.

Leggi questa versione → originale

Timeline cronologica

giovedì 30 luglio 2026·fiercepharma.com
Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
A series of label expansions for Sanofi and Regeneron’s Dupixent, including its key 2024 FDA
giovedì 30 luglio 2026·endpoints.news
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.